| Summary: | 碩士 === 國防醫學院 === 病理及寄生蟲學研究所 === 106 === Immunoglobulin A nephropathy (IgAN) is the most common glomerular disease in the world. Pathological evaluation have revealed that peri-glomerular mononuclear leukocyte infiltration, mesangial cell proliferation and glomerulus fibrosis in IgAN. Hemodialysis or kidney transplantation is required for the severe patients whose suffering from the disease on the end stage. Unfortunately, there have still no potent and safer therapeutic medication for patients even using corticosteroid, which may make more dangerously side effects. Thus, to find the way to prevent the development and progression of IgAN was necessary and emergency.
Tris (dibenzylideneacetone) dipalladium (Tris-DBA) have shown to inhibit cell growth and proliferation in melanoma and it also well-characterized as a NMT-1 inhibitor. It also inhibits the activation of inflammation pathways such as Mitogen-activated protein kinases, Phosphoinositide 3-kinase and STAT3, and inhibits cell proliferation.In this study, we evaluated the reno-protective effects of Tris-DBA in IgAN mouse model and to investigate the mechanisms of action with macrophage. Our results show that Tris-DBA could: Tris-DBA can effectively improve the pattern of IgA nephropathy in mice . (1) pathological changes of proteinuria, renal function and kidney injury；(2) infiltration of macrophages and T lymphocytes in kidney tissue and (3) kidneys Active oxides produce .
Thus, this study revealed that Tris-DBA may be a potential therapeutic medicine to improve IgA nephropathy.
|
|---|
